Adult Malignant Glioma Therapeutics Market Report 2026

The adult malignant glioma therapeutics market size has grown strongly in recent years. It will grow from $2.47 billion in 2025 to $2.7 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to limited therapeutic options for malignant gliomas, reliance on standard chemotherapy and radiotherapy, increasing prevalence of adult brain tumors, growth in hospital oncology services, rising awareness of glioma treatment needs.

The adult malignant glioma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.94 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to development of targeted molecular therapies, expansion of clinical trials for novel glioma treatments, increasing investment in precision oncology, rising collaborations between biotech and healthcare providers, adoption of advanced radiotherapy and combination therapy techniques. Major trends in the forecast period include increasing development of targeted glioma therapies, rising adoption of combination treatment approaches, expansion of experimental and personalized therapies, growing focus on improving patient quality of life, increased utilization of advanced radiotherapy techniques.

Government funding to support brain cancer research is expected to drive the growth of the adult malignant glioma therapeutics market going forward. Government funding refers to financial support provided by federal, state, or local authorities to organizations, initiatives, projects, programs, or individuals. Such funding for brain cancer research can aid the development of novel therapies, customized drug approaches, pyrimidine synthesis targeting, and orphan drug approvals for adult malignant glioma. For instance, in June 2023, the Australian Department of Health and Aged Care, an Australia-based government authority, launched the Australian Brain Cancer Mission with a fund of $136.66 million to support brain cancer research. The initiative aims to double survival rates and improve the quality of life for patients with brain cancer, including anaplastic astrocytoma. Therefore, government funding for brain cancer research is driving the adult malignant glioma therapeutics market.

Major companies operating in the adult malignant glioma therapeutics market are focusing on developing innovative products, such as small-molecule targeted degraders, to provide effective treatment solutions. A small-molecule targeted degrader is a drug that employs small molecules to induce the degradation of specific proteins by linking the protein of interest (POI) to an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a Sweden-based precision oncology company, received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BEA-17 to treat glioblastoma (GBM). BEA-17 is a small-molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST, which are implicated in the pathogenesis of various cancers, including GBM. BEA-17 functions by degrading LSD1 and CoREST, leading to the reactivation of tumor suppressor genes and inhibition of cancer cell growth.

In May 2024, Novartis, a Switzerland-based pharmaceutical company, acquired Mariana Oncology for $1 billion. The acquisition aims to strengthen Novartis’s pipeline in radioligand therapies (RLTs) for various cancers, including potential applications for solid tumors such as gliomas. Mariana Oncology is a US-based preclinical-stage biotechnology company providing therapeutics for gliomas.

Major companies operating in the adult malignant glioma therapeutics market are Johnson & Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan plc, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genentech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

North America was the largest region in the adult malignant glioma therapeutics market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adult malignant glioma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the adult malignant glioma therapeutics market by increasing costs for imported oncology drugs, radiotherapy equipment, and advanced treatment technologies. Segments such as targeted therapies and combination treatments are most impacted, with north america, europe, and asia-pacific regions facing significant import duties. These tariffs have led to higher treatment costs and delays in therapy availability. On the positive side, tariffs have encouraged local production of oncology therapeutics and investment in domestic clinical research capabilities.

The adult malignant glioma therapeutics market research report is one of a series of new reports that provides adult malignant glioma therapeutics market statistics, including adult malignant glioma therapeutics industry global market size, regional shares, competitors with a adult malignant glioma therapeutics market share, detailed adult malignant glioma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the adult malignant glioma therapeutics industry. This adult malignant glioma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An adult malignant glioma is a type of brain tumor that develops in the glial cells of the brain or spinal cord. Adult malignant glioma therapeutics refers to the range of treatment options available for malignant gliomas in adults, aiming to enhance quality of life and extend survival.

The main types of adult malignant glioma therapeutics are glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme (GBM) is an aggressive brain tumor marked by rapid growth and infiltration into surrounding brain tissue, typically without spreading to distant organs. The various therapies include chemotherapy, targeted therapy, radiotherapy, and others, and are used in hospitals, specialty clinics, cancer and radiation therapy centers, and other healthcare settings.

The adult malignant glioma therapeutics market consists of revenues earned by entities by providing services such as resection, subtotal resection, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The adult malignant glioma therapeutics market consists of sales of temozolomide, bevacizumab, carmustine, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.